Nuclear NHERF1 expression as a prognostic marker in breast cancer

Cell Death and Disease

Volumn 4, Issue 11, 2013, Pages

  Paradiso, A ^a   Scarpi, E ^b   Malfettone, A ^a   Addati, T ^a   Giotta, F ^a   Simone, G ^a   Amadori, D ^b   Mangia, A ^a  

^a NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^b DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

Author keywords

Breast cancer; EBP50; NHERF1 expression; Prognosis

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; SODIUM PROTON EXCHANGE PROTEIN 1; SODIUM PROTON EXCHANGER REGULATORY FACTOR 1; TAMOXIFEN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER PROGNOSIS; CONTROLLED STUDY; CYTOARCHITECTURE; CYTOSKELETON; DISEASE FREE SURVIVAL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR VOLUME;

ADULT; AGED; BREAST NEOPLASMS; CELL NUCLEUS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PHOSPHOPROTEINS; PROGNOSIS; SODIUM-HYDROGEN ANTIPORTER;

EID: 84889575244     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2013.439     Document Type: Article

References (32)

1. Ng CK, Pemberton HN, Reis-Filho JS. Breast cancer intratumor genetic heterogeneity: Causes and implications. Molecular Pathology Team, Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, SW3 6JB, UK. Expert Rev Anticancer Ther 2012; 12: 1021-1032
2. Aleskandarany MA, Green AR, Rakha EA, Mohammed RA, Elsheikh SE, Powe DG, et al. Growth fraction as a predictor of response to chemotherapy in node-negative breast cancer. Int J Cancer 2010; 126: 1761-1769
3. Liu J, Wei XL, Huang WH, Chen CF, Bai JW, Zhang GJ. Cytoplasmic Skp2 expression is associated with p-Akt1 and predicts poor prognosis in human breast carcinomas. PLoS One 2012; 7: E52675
4. Jonsdottir K, Zhang H, Jhagroe D, Skaland I, Slewa A, Björkblom B, et al. The prognostic value of MARCKS-like 1 in lymph node-negative breast cancer. Breast Cancer Res Treat 2012; 135: 381-390
5. Mangia A, Chiriatti A, Bellizzi A, Malfettone A, Stea B, Zito FA, et al. Biological role of NHERF1 protein expression in breast cancer. Histopathology 2009; 55: 600-608
6. Bellizzi A, Malfettone A, Cardone RA, Mangia A. NHERF1/EBP50 in Breast Cancer: Clinical Perspectives. Breast Care Basel 2010; 5: 86-90
7. Bellizzi A, Mangia A, Malfettone A, Cardone RA, Simone G, Reshkin SJ, et al. Na/H exchanger regulatory factor 1 expression levels in blood and tissue predict breast tumour clinical behaviour. Histopathology 2011; 58: 1086-1095
8. Malfettone A, Silvestris N, Paradiso A, Mattioli E, Simone G, Mangia A. Overexpression of nuclear NHERF1 in advanced colorectal cancer: Association with hypoxic microenvironment and tumor invasive phenotype. Exp Mol Pathol 2012; 92: 296-303
9. Bretscher A, Chambers D, Nguyen R, Reczek D. ERM-Merlin and EBP50 protein families in plasma membrane organization and function. Annu Rev Cell Dev Biol 2000; 16: 113-143
10. Jemth P, Gianni S. PDZ domains: Folding and binding. Biochemistry 2007; 46: 8701-8708
11. Voltz JW, Weinman EJ, Shenolikar S. Expanding the role of NHERF, a PDZ-domain containing protein adapter, to growth regulation. Oncogene 2001; 20: 6309-6314
12. Georgescu MM, Morales FC, Molina JR, Hayashi Y. Roles of NHERF1/EBP50 in cancer. Curr Mol Med 2008; 8: 459-468
13. Donowitz M, Cha B, Zachos NC, Brett CL, Sharma A, Tse CM, et al. NHERF family and NHE3 regulation. J Physiol 2005; 567: 3-11
14. Takahashi Y, Morales FC, Kreimann EL, Georgescu MM. PTEN tumor suppressor associates with NHERF proteins to attenuate PDGF receptor signalling. EMBO J 2006; 25: 910-920
15. Lazar CS, Cresson CM, Lauffenburger DA, Gill GN. The Na/H exchanger regulatory factor stabilizes epidermal growth factor receptors at the cell surface. Mol Biol Cell 2004; 15: 5470-5480
16. Mangia A, Saponaro C, Malfettone A, Bisceglie D, Bellizzi A, Asselti M, et al. Involvement of nuclear NHERF1 in colorectal cancer progression. Oncol Rep 2012; 28: 889-894
17. Mangia A, Malfettone A, Saponaro C, Tommasi S, Simone G, Paradiso A. Human epidermal growth factor receptor 2, Na/H exchanger regulatory factor 1, and breast cancer susceptibility gene-1 as new biomarkers for familial breast cancers. Hum Pathol 2011; 42: 1589-1595
18. Malfettone A, Saponaro C, Paradiso A, Simone G, Mangia A. Peritumoral vascular invasion and NHERF1 expression define an immunophenotype of grade 2 invasive breast cancer associated with poor prognosis. BMC Cancer 2012; 12: 106
19. Ediger TR, Kraus WL, Weinman EJ, Katzenellenbogen BS. Estrogen receptor regulation of the Na/H exchange regulatory factor. Endocrinology 1999; 140: 2976-2982
20. Stemmer-Rachamimov AO, Wiederhold T, Nielsen GP, James M, Pinney-Michalowski D, Roy JE, et al. NHE-RF, a merlin-interacting protein, is primarily expressed in luminal epithelia, proliferative endometrium, and estrogen receptor-positive breast carcinomas. Am J Pathol 2001; 158: 57-62
21. Song J, Bai J, Yang W, Gabrielson EW, Chan DW, Zhang Z. Expression and clinicopathological significance of oestrogen-responsive ezrin-radixin-moesin- binding phosphoprotein 50 in breast cancer. Histopathology 2007; 51: 40-53
22. Karn T, Pusztai L, Holtrich U, Iwamoto T, Shiang CY, Schmidt M, et al. Homogeneous datasets of triple negative breast cancers enable the identification of novel prognostic and predictive signatures. PLoS One 2011; 6: E28403
23. Cardone RA, Bagorda A, Bellizzi A, Busco G, Guerra L, Paradiso A, et al. Protein kinase A gating of a pseudopodial-located RhoA/ROCK/p38/NHE1 signal module regulates invasion in breast cancer cell lines. Mol Biol Cell 2005; 16: 3117-3127
24. Cardone RA, Bellizzi A, Busco G, Weinman EJ, Dell'Aquila ME, Casavola V, et al. The NHERF1 PDZ2 domain regulates PKA-RhoA-p38-mediated NHE1 activation and invasion in breast tumor cells. Mol Biol Cell 2007; 18: 1768-1780
25. Shibata T, Chuma M, Kokubu A, Sakamoto M, Hirohashi S. EBP50, a beta-cateninassociating protein, enhances Wnt signaling and is over-expressed in hepatocellular carcinoma. Hepatology 2003; 3: 178-186
26. Fraenzer JT, Pan H, Minimo Jr. L, Smith GM, Knauer D, Hung G. Overexpression of the NF2 gene inhibits schwannoma cell proliferation through promoting PDGFR degradation. Int J Oncol 2003; 23: 1493-1500
27. Hayashi Y, Molina JR, Hamilton SR, Georgescu MM. NHERF/EBP50 is a new marker in colorectal cancer. Neoplasia 2010; 12: 1013-1022
28. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003; 100: 8418-8423
29. Fouassier L, Rosenberg P, Mergey M, Saubaméa B, Clapéron A, Kinnman N, et al. Ezrin-radixin-moesin-binding phosphoprotein (EBP50), an estrogen-inducible scaffold protein, contributes to biliary epithelial cell proliferation. Am J Pathol 2009; 174: 869-880
30. Amadori D, Silvestrini R, De Lena M, Boccardo F, Rocca A, Scarpi E, et al. Randomized phase III trial of adjiuvant epirubicin followed by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) versus CMF followed by epirubicin in patients with node-negative or 1-3 node-positive rapidly proliferating breast cancer. Breast Cancer Res Treat 2011; 125: 775-784
31. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: Experience from a large study with long-Term follow-up. Histopathology 1991; 19: 403-410
32. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25: 118-145